<table>
<thead>
<tr>
<th>Study</th>
<th>Title</th>
<th>Presentation</th>
<th>Poster Schedule</th>
<th>SCRI Type</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><strong>HEMREF 09</strong> A phase I/II study of the selective phosphatidylinositol 3-kinase-delta (PI3Kδ) inhibitor, GS-1101 (CAL-101), with ofatumumab in patients with previously treated chronic lymphocytic leukemia (CLL).</td>
<td></td>
<td>Thursday 5/31  1:00-5:00pm  Location: S405</td>
<td>Phase I IST</td>
</tr>
</tbody>
</table>
|          | **CML 14** #6509^ Nilotinib vs Imatinib in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENESTnd 3-Year Follow-up | Leukemia, Myelodysplasia, and Transplantation  
Poster Discussion Session  
Time: 4:30-5:30pm  
Location: S406                                                   | Friday 6/1  1:00-5:00pm  Location: S405                                    | Phase II/III IST   |
|          | **CLL 15** #6515^ Combination of the Bruton’s Tyrosine Kinase (BTK) Inhibitor PCI-32765 (P) with Bendamustine (B)/ Rituximab(R) (R) is Active and Tolerable in Patients with Relapsed/ Refractory (R/R) Chronic Lymphocytic Leukemia (CLL), Interim Results of a Phase Ib/II study | Leukemia, Myelodysplasia, and Transplantation  
Poster Discussion Session  
Time: 4:30-5:30pm  
Location: S406                                                   | Friday 6/1  1:00-5:00pm  Location: S405                                    | Phase II/III IST   |
|          | **REFMAL 195** #3528 BRAF V600 mutant colorectal cancer (CRC) expansion cohort from the phase I/II clinical trial of BRAF inhibitor dabrafenib (GSK2118436)+MEK inhibitor trametinib (GSK1120212) | Gastrointestinal (Colorectal) Cancer  
Poster Discussion Session  
Time: 4:30-5:30pm  
Location: E. Arie Crown Theater                                                   | Friday 6/1  1:00-5:00pm  Location: E450b                                    | Phase I IST   |
|          | Career Choices: Options in Academia, Practice, Industry and Government  
Dr Howard Burris & Dr David Spigel | Career Choices in Oncology  
Education Session  
Roundtable Discussion: 5.00-6.00pm  
Location: Room S404 | Friday 6/1  3:45-6:00pm  Location: Room S404                                  | Phase I IST   |
|          | **REFMAL 141** #2516 Safety of the antimyosin G00795655 in healthy subjects and patients with advanced cancer. | Developmental Therapeutics - Clinical Pharmacology and Immunotherapy  
Poster Discussion Session/ Time: 12:00-1:00pm  
Location: S406 | Saturday 6/2  8:00am-12:00pm  Location: S405                                  | Phase I IST   |
Clinical Science Symposium  
Time: 8:00-9:30am  
Location: E Hall D2 | Saturday 6/2  8:00am-9:30am  Location: E Hall D2 | Phase I IST   |
|          | **BRE 161** #1086 Amrubicin as Second- or Third-Line Treatment for Patients with HER2-Negative Metastatic Breast Cancer (MBC): A Phase II Trial of the Sarah Cannon Research Institute (SCRI) | Breast Cancer- Triple-Negative/Cytotoxics/Local Therapy  
General Poster Session  
Time: 8:00-12.00pm  
Location: S Hall A2 | Saturday 6/2  8:00am-12.00pm  Location: S Hall A2 | Phase II/III IST   |
<table>
<thead>
<tr>
<th>BRE 166</th>
<th>#618 Use of the PRO Onc Assay (Prometheus) to measure HER2 overexpression/activation in circulating tumor cells (CTCs) in women with HER2-negative metastatic breast cancer (MBC): A Sarah Cannon Research Institute (SCRI) trial.</th>
<th>Breast Cancer - HER2/ER General Poster Session Time: 8:00-12.00pm Location: S Hall A2</th>
<th>Saturday 6/2 Time: 8:00am-12.00pm Location: S Hall A2</th>
<th>Phase II/III IIT</th>
</tr>
</thead>
<tbody>
<tr>
<td>BRE 144</td>
<td>#567 Characterization of the overall survival benefit in ENCORE 301, a randomized placebo controlled phase 2 study of exemestane with and without entinostat in ER+ postmenopausal women with metastatic breast cancer.</td>
<td>Breast Cancer - HER2/ER General Poster Session Time: 8:00am-12.00pm Location: S Hall A2</td>
<td>Saturday 6/2 Time: 8:00am-12.00pm Location: S Hall A2</td>
<td>Phase II/III IST</td>
</tr>
<tr>
<td>BRE 160</td>
<td>#TPS648 BOLERO-1: A randomized, phase III, double-blind, placebo-controlled multicenter trial of everolimus in combination with trastuzumab and paclitaxel as first-line therapy in women with HER2-positive (HER2+), locally advanced or metastatic breast cancer (BC)</td>
<td>Breast Cancer - HER2/ER General Poster Session Time: 8:00am-12.00pm Location: S Hall A2</td>
<td>Saturday 6/2 Time: 8:00am-12.00pm Location: S Hall A2</td>
<td>Phase II/III IST</td>
</tr>
<tr>
<td>MM 29</td>
<td>#8033 Oral weekly MLN9708, an investigational proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients (pts) with previously untreated multiple myeloma (MM): a phase 1/2 study</td>
<td>Lymphoma and Plasma Cell Disorders Poster Discussion Session Time: 12:00pm-1.00pm Location: E354a</td>
<td>Saturday 6/2 Time: 8:00am-12.00pm Location: E450b</td>
<td>Phase II/III IST</td>
</tr>
<tr>
<td>MM 29</td>
<td>#551 Safety of everolimus for women over 65 years of age with advanced breast cancer (BC): 12.5-mo follow-up of BOLERO-2.</td>
<td>Breast Cancer - HER2/ER General Poster Session Time: 8:00am-12.00pm Location: S Hall A2</td>
<td>Saturday 6/2 Time: 8:00am-12.00pm Location: S Hall A2</td>
<td>Phase II/III IST</td>
</tr>
<tr>
<td>REFMAL 183</td>
<td>#535 Activity of cabozantinib (XL184) in metastatic breast cancer (MBC): Results from a phase 2 randomized discontinuation trial (RDT).</td>
<td>Breast Cancer - HER2/ER Poster Discussion Session/Time: 4:45-5:45pm Location: E Hall D2</td>
<td>Saturday 6/2 Time: 1:15-5:15pm Location: E450a</td>
<td>Phase I IST</td>
</tr>
<tr>
<td>REFMAL 209</td>
<td>#3023 A five-arm, open-label, phase 1/ib study to assess safety and tolerability of oral MEK1/MEK2 inhibitor trametinib (GSK1120212) in combination with chemotherapy or erlotinib in patients with advanced solid tumors.</td>
<td>Developmental Therapeutics - Experimental Therapeutics Poster Discussion Session/Time: 4:45-5:45pm Location: S406</td>
<td>Saturday 6/2 Time: 1:15-5:15pm Location: S405</td>
<td>Phase I IST</td>
</tr>
<tr>
<td>REFMAL 245</td>
<td>#3021</td>
<td>A Phase ib study of the Akt inhibitor GDC-0068 with docetaxel (D) or mFOLFOX-6 (F) in patients with advanced solid tumors.</td>
<td>Developmental Therapeutics - Experimental Therapeutics Poster Discussion Session Time: 4:45-5:45pm Location: S406</td>
<td>Saturday 6/2 Display: 1:15-5:15pm Location: S405</td>
</tr>
<tr>
<td>BRE 162</td>
<td>#512</td>
<td>Effects of everolimus (EVE) on disease progression in bone and bone markers (BM) in patients (pts) with bone metastases (mets).</td>
<td>Breast - HER2/ER Poster Discussion Session Time: 4:45-5:45pm Location: E Hall D2</td>
<td>Saturday 6/2 Display: 1:15-5:15pm Location: E450a</td>
</tr>
<tr>
<td>MEL 19</td>
<td>#8556</td>
<td>Everolimus in Combination with Paclitaxel and Carboplatin in Patients with Metastatic Melanoma: A Phase II Trial of the Sarah Cannon Research Institute (SCRI)</td>
<td>Melanoma/Skin Cancers General Poster Session Time: 8:00am-12:00pm Location: S Hall A2</td>
<td>Sunday 6/3 Time: 8:00am-12:00pm Location: S Hall A2</td>
</tr>
<tr>
<td>MEL 26</td>
<td>#8567</td>
<td>A single-arm, open label, US expanded access study of vemurafenib in patients with metastatic melanoma</td>
<td>Melanoma/Skin Cancers General Poster Session Time: 8:00am-12:00pm Location: S Hall A2</td>
<td>Sunday 6/3 Time: 8:00am-12:00pm Location: S Hall A2</td>
</tr>
<tr>
<td>SKIN 01</td>
<td>#8579</td>
<td>Efficacy and safety of the hedgehog pathway inhibitor vismodegib in patients with advanced basal cell carcinoma (BCC): ERIVANCE BCC study update</td>
<td>Melanoma/Skin Cancers General Poster Session Time: 8:00am-12:00pm Location: S Hall A2</td>
<td>Sunday 6/3 Time: 8:00am-12:00pm Location: S Hall A2</td>
</tr>
<tr>
<td>REFMAL 198</td>
<td>#3006</td>
<td>Phase 1 Trial of an oral TORC1/TORC2 Inhibitor (CC-223) in advanced solid and hematologic cancers Developmental Therapeutics - Experimental Therapeutics Oral Abstract Session Time: 9:45am-12:45pm Location: E. Arie Crown Theater</td>
<td>Sunday 6/3 Time: 9:45am-12:45pm Location: E. Arie Crown Theater</td>
<td>Phase I IST</td>
</tr>
<tr>
<td>REFMAL 249</td>
<td>#3000</td>
<td>Phase 1 clinical and pharmacological study of the focal adhesion kinase (FAK) inhibitor GSK2256098 in pts with advanced solid tumors. Developmental Therapeutics - Experimental Therapeutics Oral Abstract Session Time: 9:45am-12:45pm Location: E. Arie Crown Theater</td>
<td>Sunday 6/3 Time: 9:45am-12:45pm Location: E. Arie Crown Theater</td>
<td>Phase I IST</td>
</tr>
<tr>
<td>BEST OF ASCO</td>
<td>LBA3501</td>
<td>Results of the X-PECT Study: A phase III randomized double-blind placebo-controlled study of perifosine plus capecitabine (P-CAP) vs. placebo plus capecitabine (CAP) in patients (pts) with refractory metastatic colorectal cancer (mCRC) Gastrointestinal (Colorectal) Cancer Oral Abstract Session Time: 9:45am-12:45pm Location: E Hall D1</td>
<td>Sunday 6/3 Time: 9:45am-12:45pm Location: E Hall D1</td>
<td>Phase II/III IST</td>
</tr>
<tr>
<td>GI 161</td>
<td>#3631</td>
<td>A phase 1 dose-escalation study of TAS-102 in patients with refractory metastatic colorectal cancer. Gastrointestinal (Colorectal) Cancer General Poster Session Time: 8:00am-12:00pm Location: S Hall A2</td>
<td>Monday 6/4 Time: 8:00am-12:00pm Location: S Hall A2</td>
<td>Phase I IST</td>
</tr>
<tr>
<td>GI 82</td>
<td>#3543</td>
<td>Phase 1b Study of Dulanermin Combined with FOLFIRI (± Bevacizumab [BV]) in Previously Treated Patients (Pts) with Metastatic Colorectal Cancer (mCRC) Gastrointestinal (Colorectal) Cancer General Poster Session Time: 8:00am-12:00pm Location: S Hall A2</td>
<td>Monday 6/4 Time: 8:00am-12:00pm Location: S Hall A2</td>
<td>Phase I IST</td>
</tr>
<tr>
<td>REFMAL 154</td>
<td>#3077</td>
<td>Tumor drug distribution and target engagement of MLN9708, an investigational proteasome inhibitor, in patients with advanced solid tumors. Developmental Therapeutics - Experimental Therapeutics General Poster Session Time: 8:00am-12:00pm Location: S Hall A2</td>
<td>Monday 6/4 Time: 8:00am-12:00pm Location: S Hall A2</td>
<td>Phase I IST</td>
</tr>
<tr>
<td>REFMAL 156</td>
<td>#3062</td>
<td>Open-label extension study of the RNAi therapeutic ALN-VSP02 in cancer patients responding to therapy. Developmental Therapeutics - Experimental Therapeutics General Poster Session Time: 8:00am-12:00pm Location: S Hall A2</td>
<td>Monday 6/4 Time: 8:00am-12:00pm Location: S Hall A2</td>
<td>Phase I IST</td>
</tr>
<tr>
<td>REFMAL 182</td>
<td>#2566</td>
<td>A first-in human phase Ib study to evaluate the MEK inhibitor GDC-0973, combined with the pan-Pi3K inhibitor GDC-0941, in patients with advanced solid tumors. Developmental Therapeutics - Clinical Pharmacology and Immunotherapy General Poster Session Time: 8:00am-12:00pm Location: S Hall A2</td>
<td>Monday 6/4 Time: 8:00am-12:00pm Location: S Hall A2</td>
<td>Phase I IST</td>
</tr>
<tr>
<td>RefMAL</td>
<td>#2579 Targeting hyaluronan (HA) in tumor stroma. A phase 1 study to evaluate the safety, pharmacokinetics (PK), and pharmacodynamics of pegylated hyaluronidase (PEGPH20) in patients with solid tumors.</td>
<td>Developmental Therapeutics - Clinical Pharmacology and Immunotherapy General Poster Session Time: 8:00am-12:00pm Location: S Hall A2</td>
<td>Monday 6/4 Phase I IST</td>
<td></td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td></td>
</tr>
<tr>
<td>RefMAL 212</td>
<td>#TPS2621 Safety, pharmacokinetics, and antitumor activity of MEDI3617, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors.</td>
<td>Developmental Therapeutics - Clinical Pharmacology and Immunotherapy General Poster Session Time: 8:00am-12:00pm Location: S Hall A2</td>
<td>Monday 6/4 Phase I IST</td>
<td></td>
</tr>
<tr>
<td>RefMAL 226</td>
<td>#3041 Phase 1, first-in-human trial of an oral VEGFR tyrosine kinase inhibitor (TKI) x-82 in patients with advanced solid tumors.</td>
<td>Developmental Therapeutics - Experimental Therapeutics General Poster Session Time: 8:00am-12:00pm Location: S Hall A2</td>
<td>Monday 6/4 Phase I IST</td>
<td></td>
</tr>
<tr>
<td>RefMAL 230</td>
<td>#TPS3118 Phase Ib combination trial of a MEK inhibitor, pimasertib (MSC1936369B), and a PI3K/mTOR inhibitor SAR245409 in patients with solid tumors.</td>
<td>Developmental Therapeutics - Experimental Therapeutics General Poster Session Time: 8:00am-12:00pm Location: S Hall A2</td>
<td>Monday 6/4 Phase I IST</td>
<td></td>
</tr>
<tr>
<td>RefMAL 252</td>
<td>#3067 ME-143, a novel inhibitor of tumor specific NADH oxidase (tnNOX): results from a first-in-human phase I study.</td>
<td>Developmental Therapeutics - Experimental Therapeutics General Poster Session Time: 8:00am-12:00pm Location: S Hall A2</td>
<td>Monday 6/4 Phase I IST</td>
<td></td>
</tr>
<tr>
<td>N/A</td>
<td>#2540 Prediction of early death among patients (pts) enrolled in phase I trials: Development and validation of a new model based on platelet count and albumin levels</td>
<td>Developmental Therapeutics - Clinical Pharmacology and Immunotherapy General Poster Session Time: 8:00am-12:00pm Location: S Hall A2</td>
<td>Monday 6/4 Phase I IST</td>
<td></td>
</tr>
<tr>
<td>GI 135</td>
<td>#4127 Bevacizumab, Pertuzumab, and Sandostatin for Patients (pts) with Advanced Neuroendocrine Cancers (NET)</td>
<td>Gastrointestinal (Noncolorectal) Cancer General Poster Session Time: 8:00am-12:00pm Location: S Hall A2</td>
<td>Monday 6/4 Phase II/III IIT</td>
<td></td>
</tr>
<tr>
<td>GI 155</td>
<td>#4130 Patients with Carcinoma of Unknown primary and &quot;colon cancer profile&quot;: clinicopathologic features and survival data</td>
<td>Gastrointestinal (Noncolorectal) Cancer General Poster Session Time: 8:00am-12:00pm Location: S Hall A2</td>
<td>Monday 6/4 Phase II/III IIT</td>
<td></td>
</tr>
<tr>
<td>BEST OF ASCO CLL 14</td>
<td>#6507 The Bruton's tyrosine kinase (BTK) inhibitor PCI-32765 (P) in treatment-naive (TN) chronic lymphocytic leukemia (CLL) patients (pts): Interim results of a phase Ib/II study</td>
<td>Leukemia, Myelodysplasia, and Transplantation Oral Abstract Session Time: 8:00-11:00am Location: E354a</td>
<td>Monday 6/4 Phase II/III IST</td>
<td></td>
</tr>
<tr>
<td>GI 155</td>
<td>#TPS3640 A randomized, phase II, multicenter, double-blind, placebo-controlled study evaluating onartuzumab (MetMAb) in combination with mFOLFOX6 plus bevacizumab in patients with metastatic colorectal cancer</td>
<td>Gastrointestinal (Colorectal) Cancer General Poster Session Time: 8:00am-12:00pm Location: S Hall A2</td>
<td>Monday 6/4 Phase II/III IST</td>
<td></td>
</tr>
<tr>
<td>GI 155</td>
<td>#TPS2615 A Phase 1 Study of BMS-936558 in Combination with Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, or Carboplatin/Paclitaxel in Patients with</td>
<td>Developmental Therapeutics - Clinical Pharmacology and Immunotherapy General Poster Session Time: 8:00am-12:00pm Location: S Hall A2</td>
<td>Monday 6/4 Phase II/III IST</td>
<td></td>
</tr>
<tr>
<td>REFMAL 233</td>
<td>Treatment-Naive, Stage IIIB/IV Non-Small Cell Lung Cancer</td>
<td>Time: 8:00am-12:00pm Location: S Hall A2</td>
<td>Monday 6/4</td>
<td>Phase I IIT</td>
</tr>
<tr>
<td>#3097 PI3K/mTOR Inhibitor BEZ235 Given Twice Daily for the Treatment of Patients (pts) with Advanced Solid Tumors</td>
<td>Developmental Therapeutics - Experimental Therapeutics General Poster Session Time: 8:00am-12:00pm Location: S Hall A2</td>
<td>Monday 6/4</td>
<td>Phase I IIT</td>
<td></td>
</tr>
<tr>
<td>T-DM1: Hitching A Ride On a Therapeutic Antibody</td>
<td>Antibody Conjugates: Target Therapy Meets Chemo in One Drug Education Session/Oral Presentation Time: 10:05-10.25am Location: E354b</td>
<td>Monday 6/4</td>
<td>Phase II/III IIT</td>
<td></td>
</tr>
<tr>
<td>#1018 Everolimus with Paclitaxel plus Bevacizumab as First-Line Therapy for HER2-Negative Metastatic Breast Cancer (MBC): A Randomized, Double Blind, Placebo Controlled Phase II Trial of the Sarah Cannon Research Institute (SCRI)</td>
<td>Breast Cancer - Triple-Negative/Cytotoxics/Local Therapy Poster Discussion Session Time: 4:45-5:45pm Location: N Hall B1</td>
<td>Monday 6/4</td>
<td>Phase II/III IIT</td>
<td></td>
</tr>
<tr>
<td>#TPS8115 A single-arm, open-label, multicenter phase I/II study of the combination of panobinostat (pan) and carfilzomib (cfz) in patients (pts) with relapsed/refractory multiple myeloma (RR MM)</td>
<td>Lymphoma and Plasma Cell Disorders General Poster Session Time: 1:15pm-5:15pm Location: S Hall A2</td>
<td>Monday 6/4</td>
<td>Phase II/III IIT</td>
<td></td>
</tr>
<tr>
<td>#TPS6636 A single-arm, open-label, multicenter study of complete molecular response (CMR) in patients with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia in chronic phase (CML-CP) treated with nilotinib</td>
<td>Leukemia, Myelodysplasia, and Transplantation General Poster Session Time: 1:15pm-5:15pm Location: S Hall A2</td>
<td>Monday 6/4</td>
<td>Phase II/III IST</td>
<td></td>
</tr>
<tr>
<td>#4027 Multicenter Randomized Phase II trial of Cisplatin, Irinotecan plus Bevacizumab (PCA) vs. Docetaxel, Cisplatin, Irinotecan plus Bevacizumab (TPCA) in patients (pts) with Metastatic Esophagogastric Cancer (MEGCA)</td>
<td>Gastrointestinal (Noncolorectal) Cancer Poster Discussion Session Time: 4:45-5:45pm Location: N Hall D1</td>
<td>Monday 6/4</td>
<td>Phase II/III IST</td>
<td></td>
</tr>
<tr>
<td>#8081 Efficacy of ocaratuzumab, (AME-133v), in relapsed follicular lymphoma patients refractory to prior rituximab</td>
<td>Lymphoma and Plasma Cell Disorders General Poster Session Time: 1:15pm-5:15pm Location: S Hall A2</td>
<td>Monday 6/4</td>
<td>Phase II/III IST</td>
<td></td>
</tr>
<tr>
<td>#4014 Multivariate analysis including biomarkers in the phase III RADIANT-2 study of octreotide LAR plus everolimus (E+O) or placebo (P+O) among patients with advanced neuroendocrine tumors (NET)</td>
<td>Gastrointestinal (Noncolorectal) Cancer Poster Discussion Session Time: 4:45-5:45pm Location: E Hall D1</td>
<td>Monday 6/4</td>
<td>Phase II/III IST</td>
<td></td>
</tr>
<tr>
<td>#6122 Variation in health-related quality of life (HRQOL) by ECOG performance status (PS) and fatigue among patients with chronic lymphocytic leukemia (CLL).</td>
<td>Health Services Research General Poster Session Time: 1:15pm-5:15pm Location: S Hall A2</td>
<td>Monday 6/4</td>
<td>Phase II/III IST</td>
<td></td>
</tr>
<tr>
<td>#10584 Estimation of expected survival time using gene expression profiling for tumor site origin.</td>
<td>Tumor Biology General Poster Session Time: 1:15-5:15pm Location: S Hall A2</td>
<td>Monday 6/4</td>
<td>Phase II/III IST</td>
<td></td>
</tr>
<tr>
<td>REFMAL 195</td>
<td>#8510 Updated safety and efficacy results from a Phase I/II study of the oral BRAF inhibitor dabrafenib (GSK2118436) combined with the oral MEK 1/2 inhibitor trametinib (GSK1120212) in patients with BRAFi-naive metastatic melanoma.</td>
<td>Mutated Melanoma: The Role for MEK Inhibitors Clinical Science Symposium Time: 3:00pm-4:30pm Location: E354a</td>
<td>Monday 6/4 Time: 3:00pm-4:30pm Location: E354a</td>
<td>Phase I IIT</td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td>UNKPRI 20a</td>
<td>#10530 Molecular Gene Expression Profiling to Predict the Tissue of Origin and Direct Site-Specific Therapy in Patients (pts) with Carcinoma of Unknown Primary Site (CUP): Results of a prospective Sarah Cannon Research Institute (SCRI) trial.</td>
<td>Tumor Biology Poster Discussion Session Time: 11:30am-12:30pm Location: S100a</td>
<td>Tuesday 6/5 Time: 8:00am-12:00pm Location: S102</td>
<td>Phase II/III IIT</td>
</tr>
<tr>
<td></td>
<td>Breaching the Castle Wall: The Blood-Brain Barrier Dr Jeffrey Infante</td>
<td>“Inclusion of Patients with Brain Metastases in Clinical Trials” Education Session/Oral Presentation Time: 9:45-11:00am Location: E354b</td>
<td>Tuesday 6/5 Time: 9:45-11:00am Location: E354b</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Personalized Oncology for Colorectal Cancer: Ready for Prime Time or Stop the Train? Dr Johann Bendell</td>
<td>Gastrointestinal (Colorectal) Cancer, Developmental Therapeutics, Core Sessions Education Session/Oral Presentation Time: 8:20-8:40am Location: S406</td>
<td>Tuesday 6/5 Time: 8:00-9:15am Location: S406</td>
<td></td>
</tr>
</tbody>
</table>